Drug Trial Radar · NCT06311578
A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
126
Planned (sponsor's estimate)
Start
Apr 10, 2024
Primary completion
Nov 8, 2028
Study completion Feb 14, 2033
Sponsor
- Lead sponsor
- Johnson & Johnson Enterprise Innovation Inc.Johnson & Johnson (Janssen) (JNJ)
- Sponsor type
- Industry
- First posted
- Mar 15, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Non randomized
- Model
- Sequential
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to determine the safety, feasibility, recommended dose(s) and regimen(s) of JNJ-87704916 as monotherapy and in combination with cetrelimab.
Conditions
- Neoplasms
Interventions
JNJ-87704916Drug
JNJ-87704916 will be administered as an intratumoral injection.
CetrelimabDrug
Cetrelimab will be administered.
Standard of Care PD(L)-1Drug
Frontline anti-PD(L)-1 antibody therapy will be administered as standard of care treatment.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Part 1: Number of Participants with Dose-Limiting Toxicity (DLT)Time frame: Up to 5 years
- Number of Participants with Adverse Events (AEs) by SeverityTime frame: From first dose up to 100 days after last dose of study treatment (up to 5 years)
Locations
10 sites in 4 countries. Site status is shown where the registry gives one.
NYU Langone Health
New York, New York · Recruiting
Fox Chase Cancer Center
Philadelphia, Pennsylvania · Suspended
UPMC Cancer Centers
Pittsburgh, Pennsylvania · Recruiting
MD Anderson Cancer Center
Houston, Texas · Recruiting
Toronto General Hospital
Toronto, Ontario, Canada · Recruiting
Centre Hospitalier de l'Universite de Montreal
Montreal, Quebec, Canada · Recruiting
Gustave Roussy
Villejuif, France · Recruiting
Hosp Univ Vall D Hebron
Barcelona, Spain · Recruiting
Hosp Univ Fund Jimenez Diaz
Madrid, Spain · Recruiting
Hosp Univ Hm Sanchinarro
Madrid, Spain · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.